

**Project on**  
**Literature review on recent outbreak of monkey pox**



[In the partial fulfillment of the requirements for the degree of Bachelor  
of Pharmacy]

Submitted To

The Department of Pharmacy,  
Faculty of Allied Health Sciences,  
Daffodil International University

Submitted By

Rabeya Sultana Rumi  
Student ID:191-29-1422  
Batch: 21(B)

Department of Pharmacy,  
Faculty of Allied Health Sciences,  
Daffodil International University

.....  
**May 2023**

## **Approval**

This project paper, “**Literature review on recent outbreak of monkey pox**”, submitted to the Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, has been accepted as satisfactory for the partial fulfillment of the requirements for the degree of Bachelor of Pharmacy and approved as to its style and contents.

### BOARD OF EXAMINERS

.....

Dr. Muniruddin Ahmed  
Professor and Head,  
Department of Pharmacy,  
Faculty of Allied Health Sciences,  
Daffodil International University

..... Internal Examiner 1

..... Internal Examiner 2

..... External Examiner 3

## Declaration

I hereby declare that this project report, “**Literature review on recent outbreak of monkey pox**”, is done by me under the supervision of Mr. Pollob Ahmed Shuvo Lecturer, Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University. I am declaring that this Project is my original work. I also declare that neither this project nor any part thereof has been submitted elsewhere for the award of Bachelor or any degree.

Supervised By



.....

Mr. Pollob Ahmed Shuvo


Lecturer

Department of Pharmacy

Faculty of Allied Health Sciences

Daffodil International University

Submitted By



.....

Rabeya Sultana Rumi

ID: 191-29-1422

Department of Pharmacy

Faculty of Allied Health Sciences

Daffodil International University

## **Acknowledgement**

I might want to communicate my profound applause to the All-powerful Allah who has given me the capacity to finish my undertaking work and the chance to concentrate in this subject.

I'm a lot of thankful to my honorable project supervisor of Mr. Pollob Ahmed Shuvo Lecturer, Department of Pharmacy, Daffodil International University for her brilliant direction and steady oversight just as for giving essential data in regards to the task and furthermore for her help in finishing the project.

I would like to express my humble regards to Dr. Muniruddin Ahmed, Professor and Head, Department of Pharmacy, Daffodil International University.

I also wish to offer my respect to all of the teachers of Pharmacy Department, Daffodil International University and thankful to other members for their excellent cooperation with us.

Finally, I would like to express my gratitude towards my parents and other family members for their kind cooperation and encouragement which helped me in completion of this project.

**Dedication.....**

My Parents

The persons who always encourage me in every sphere of my life.

## Abstract

**Background:** An ongoing outbreak of monkey pox, a viral disease then commonly known as “monkey pox”, was confirmed in May 2022. Some of the symptoms include a high temperature, enlarged lymph nodes, and a rash that starts out as blisters before becoming crusty. A more recent vaccine for smallpox and monkey pox that is based on modified vaccinia Ankara has been given the green light for use, but there is only a limited supply of it.

**Objectives:** The present article focuses on the death caused by monkey pox globally, clinical characteristics of monkey pox, therapies for the management of monkey pox.

**Method:** A framework of research methodologies, as well as methods for gathering and analyzing data, is provided by a methodological review. A search was done using keywords such "Monkey pox and Smallpox," "therapies of monkey pox," in online search engines, academic bibliographic databases, PubMed, and Medline.

**Results:** In 2022, monkey pox spread widely, with most victims residing in Africa. The incubation times for smallpox, monkey pox, and varicella are 7–17 days, 10–21 days, and 10–21 days, respectively. Smallpox, monkey pox, and varicella all cause rashes that last 14–28 days, 10–21 days, and 10–21 days, respectively. Smallpox and monkey pox prodromal fevers reach fever levels of over 40°C, whereas varicella prodromal fever is mild. Moreover, the varicella virus increases body temperatures to a maximum of 38.8°C, which are often between 38.5°C and 40.5°C. According to a review study, the first antiviral authorized for the treatment of smallpox in adults and pediatric patients weighing at least 3 kg is Tecovirimat (also known as TPOXX or ST-246), which is regarded as the preferred treatment.

**Conclusion:** Monkey pox is a rare viral disease that mostly affects remote areas of Central and West Africa. One technique of protection is avoiding contact with animals that might be infected with the virus. There is a monkey pox vaccine, however it is mostly used in clinical and laboratory settings and is not often available to the general public.

## Contents

<b>Chapter One</b> .....	1
<b>Introduction</b> .....	1
1.1 Virus .....	2
1.2 Origins .....	4
1.3 Classifications of viruses .....	5
<b>Chapter Two</b> .....	6
<b>Literature Review</b> .....	6
2.1 Monkeypox .....	7
2.2 Signs and symptoms .....	8
2.3 Causes .....	9
2.4 Diagnosis .....	10
2.5 Risk Factors .....	11
2.6 Prevention .....	11
2.7 Treatment.....	13
2.8 Monkeypox virus .....	13
2.9 Virology.....	15
<b>Chapter Three</b> .....	17
<b>Purpose of the study</b> .....	17
3.1 Purpose of the study .....	18
<b>Chapter Four</b> .....	19
<b>Methodology</b> .....	19
4.1 Introduction: .....	20
4.2 Research Design: .....	20

4.3 Method of Data Analysis: .....	20
4.4 Ethical Considerations: .....	20
<b>Chapter Five</b> .....	21
<b>Result and Discussion</b> .....	21
5.1 Deaths caused by monkey pox globally .....	22
5.2. Clinical Characteristics of Smallpox, Monkeypox, and Varicella .....	22
5.3 Summary of therapies for the management of monkeypox.....	23
5.4 Monkeypox Patients with Seminal Fluid Viral DNA.....	24
<b>Chapter 6</b> .....	25
<b>Conclusion</b> .....	25
6.1 Conclusion.....	26
<b>Chapter seven</b> .....	27
<b>Reference</b> .....	27
7.1 Reference .....	28

## List of figures

Figure 1: Viruses.....	3
Figure 2: Monkeypox.....	8
Figure 3: PCR Test.....	10
Figure 4: Respirator .....	12
Figure 5: Tecovirimat .....	13
Figure 6: Monkeypox virus.....	14
Figure 7: Orthopoxvirus.....	15
Figure 8: Poxviruses .....	16



## List of tables

Table 1: Deaths caused by monkey pox globally	22
Table 2: Clinical Characteristics of Smallpox, Monkeypox, and Varicella .....	22
Table 3: Summary of therapies for the management of monkeypox.....	23
Table 4: Monkeypox Patients with Seminal Fluid Viral DNA.....	24

# **Chapter One**

## **Introduction**

## 1.1 Virus

Viruses are very small infectious organisms that can only multiply inside the cells of a living host. Viruses can only infect living cells. [1] Viruses are a danger to every living creature on Earth, from macroorganisms like animals and plants to microorganisms like bacteria and archaea. They may cause disease in all of these different types of organisms.[2] Since Dmitri Ivanovsky's 1892 article describing a non-bacterial pathogen infecting tobacco plants and Martinus Beijerinck's 1898 discovery of the tobacco mosaic virus,[3] more than 9,000 virus species have been described in detail,[4] with the Zika virus being the most recent to be described in 2006. There are millions of different types of viruses in the environment, but since Martinus Beijerinck's 1898 discovery of the tobacco mosaic virus and D [5-6] Viruses are the most common kind of living entity and may be discovered in practically every setting on Earth. They are responsible for almost all disease. [7] [8] The study of viruses is the primary focus of the sub discipline of microbiology known as virology. When a cell gets infected with a virus, it is sometimes required to produce thousands of copies of the original virus in an extremely short amount of time. Independent particles, also known as virions, may be seen most of the time when a virus is not present inside an infected cell or when it is not in the process of infecting a cell. I the genetic material, which is made up of long molecules of DNA or RNA that encode the structure of the proteins by which the virus acts; ii the capsid, which is a protein coat that surrounds and protects the genetic material; and iii, in some cases, an outer envelope made of lipids. These particles make up the virus. I the genetic material, which is made up of long molecules of DNA or RNA that encode the structure of the proteins by which the virus acts. These viral particles have the potential to assume a broad variety of forms, ranging from the simplest helical and icosahedral structures to more sophisticated geometrical arrangements. It is not feasible to view the virions of most virus species with an optical microscope since the virions of most virus species are one tenth the size of most bacteria. Plasmids are mobile fragments of DNA, and it's possible that certain viruses arose from them. Other viruses, on the other hand, could have come from bacteria. In the same way that the horizontal transmission of genes by viruses is essential to the evolutionary processes that take place, genetic diversity may be increased via sexual reproduction. [9-10] Some scientists believe that viruses are living forms

despite the fact that they lack fundamental characteristics, such as cell structure, that are generally considered to be crucial requirements for defining life. These characteristics include the ability to reproduce, pass on genetic information to offspring, and evolve as a result of natural selection.




Figure 1: Viruses

Replicators and "organisms on the edge of life" are two names that have been given to viruses due to the fact that they share some of these features but not others. [11] There are many different kinds of carriers that viruses may employ to spread. Vectors are organisms that carry diseases and have the potential to transmit them to other hosts. For instance, aphids and other insects that feed on plant sap have the potential to transmit viruses from one plant to another, and blood-sucking insects have the potential to transmit viruses from one mammal to another. The common cold, SARS-CoV-2, chickenpox, smallpox, and measles are only few of the viruses that may be spread via the air by coughing and sneezing. Other viruses that can be spread include the common cold and smallpox. Noroviruses and rotaviruses are the two viruses that are responsible for the vast majority of cases of viral gastroenteritis. Viral gastroenteritis may be caused by a variety of other viruses. It takes far less than one hundred norovirus particles to get a person sick with the sickness. [12] HIV is only one of several viruses that may be spread via sexual contact or blood contact. The "host range" of a virus refers to the many kinds of cells that it is capable of infecting. If a virus can only infect a limited number of species, then its host range is considered to be confined. On the other hand, if it can infect a vast variety of organisms, then its host range is considered to be broad. When a virus infects an animal, the body generates an immune response in an effort to clear itself of the foreign invader and prevent further infection. Vaccines, which offer an immunity against a particular viral infection that is intentionally acquired, may also be used to induce immune responses in the

recipient. Viruses such as HIV/AIDS, human papillomavirus (HPV), and hepatitis viruses, on the other hand, are able to circumvent these defenses and live within the body for lengthy periods of time. In order to battle viruses, researchers have developed a variety of distinct classes of antiviral medications. [13]

## 1.2 Origins

Viruses are ubiquitous in the biosphere and have likely been there from the earliest days of cellular existence. [14] Since viruses cannot leave fossils, scientists have to resort to molecular methods to learn about their early history. [15] Furthermore, viruses are often able to integrate their genetic material into the germline of their host species, allowing them to be passed on to subsequent generations of the host's progeny. This offers paleo virologists with a goldmine of data for reconstructing the history of viruses that have been around for millions of years. There are three primary theories that attempt to clarify where viruses came from: [16-17]

- A. Regressive hypothesis -Perhaps viruses evolved from smaller cells that parasitized bigger ones. As time went on, parasitism-unrelated genes were eliminated. Both rickettsia and chlamydia are examples of bacteria, and like viruses, they can only multiply while within a host cell. They provide credence to the theory, since they presumably lost genes that allowed them to thrive outside of a cell due to their need on parasitism. Sometimes referred to as the "degeneracy hypothesis"[18-19] or the "reduction hypothesis," this idea goes by a few different names. [20]

### B. Cellular origin hypothesis

The genetic material of one creature may have "escaped" and given rise to the genes of a virus. Potential sources of the escaping DNA include plasmids and transposons. Plasmids are mobile bits of bare DNA that may jump from cell to cell (molecules of DNA that replicate and move around to different positions within the genes of the cell). [21] Transposons, which were once referred to as "jumping genes," are an example of mobile genetic components and may represent the virus's original source. Barbara McClintock first noticed them in maize in the year 1950. The term "vagrancy hypothesis" has been used to describe this phenomenon [22]. This is known as "escape hypothesis" for short. [23]

Co-evolution hypothesis - One alternative name for this idea is the "virus-first hypothesis." suggests that viruses depended on cellular life for billions of years since they emerged from complex molecules of protein and nucleic acid at the same time cells first arose on Earth. Viroids are non-viral RNA molecules. This is because they do not have a protein coat, which is a characteristic

shared by viruses. They are sometimes referred to as subviral agents since they share properties with many viruses. Plants are susceptible to a wide variety of viral diseases. [24] They connect with the host cell and replicate with the help of the host cell's machinery but lack their own coding for proteins. [25] The human hepatitis delta virus shares an RNA genome with viroids but uses a protein coat borrowed from the hepatitis B virus rather than producing its own. A flawed virus is what this is. Even though the hepatitis delta virus DNA may reproduce on its own once within a host cell, the virus cannot infect new cells without the protein coat provided by the hepatitis B virus. [26] Mimivirus, which infects the protozoan *Acanthamoeba castellanii*, is also required for the survival of the sputnik virophage. [27] These viruses, known as "satellites," are reliant on the existence of other viral species in the host cell and may represent evolutionary intermediates between viroids and viruses. [28-29] All of these theories had issues in the past, for example, the regressive theory failed to explain why even the tiniest cellular parasites are not similar to viruses. The intricate capsids and other viral particle structures could not be explained by the escape concept. By definition, viruses can only replicate inside of living host cells, hence the virus-first idea ran counter to this fact. It is now understood that viruses predate the separation of life into the three domains and have existed for a very long time. This new information has caused virologists to reevaluate and rethink three long-held theories. Such studies have not settled the debate over which of these theories is more accurate. [31] It's very improbable that all known viruses descended from a single source, and it's possible that viruses have repeatedly emerged in the past via several ways. [32]

### **1.3 Classifications of viruses**

- a) Class I: Double stranded DNA (dsDNA) viruses.
- b) Class II: Single stranded DNA (ssDNA) viruses.
- c) Class III: Double stranded RNA (dsRNA) viruses.
- d) Class IV: Single stranded RNA (ssRNA) viruses.
- e) Class V: Single stranded RNA (ssRNA) viruses.

# **Chapter Two**

## Literature Review

## **2.1 Monkeypox**

The illness known as monkeypox is caused by a virus that is contagious and may affect both people and other animals. Some of the symptoms include a high temperature, enlarged lymph nodes, and a rash that starts out as blisters before becoming crusty. The time it takes for symptoms to appear after exposure might vary anywhere from five to twenty-one days. [33] The average length of time that symptoms last is between two and four weeks. There may be just a few, moderate signs, or it may take place with no symptoms at all being recognized. [34] It has been discovered that the characteristic presentation of shingles, which consists of fever and muscular aches, followed by swollen glands, and lesions all occurring at the same stage, is not present in every outbreak. Some cases, particularly those affecting youngsters, pregnant women, or those with compromised immune systems, may be quite serious. This illness is brought on by the monkeypox virus, which belongs to the genus Orthopoxvirus and is a zoonotic virus. [35] This genus also contains the variola virus, which is responsible for causing the disease known as smallpox. Of the two forms that may affect humans, clade II (previously known as the West African clade) is associated with an illness that is less severe than the one that originates in Central Africa (the Congo basin). Transmission from infected animals may occur via the handling of contaminated meat, as well as through bites and scratches. Transmission from one individual to another may take place when a person is exposed to infected bodily fluids or contaminated items, when there is a little droplet-to-droplet contact, or even by the airborne route. The virus may be passed from person to person from the time symptoms first appear until all of the lesions have crusted over and fallen off; however, there is evidence of dissemination for more than a week after lesions have crusted over. The diagnosis may be verified by doing a DNA test on a lesion to look for the virus. Nobody has found a treatment that works. A research that was conducted in 1988 indicated that the smallpox vaccination had a protective efficacy of around 85% when it came to avoiding infection in people who were in close contact with one another and reducing the severity of the illness. [36] A more recent vaccine for smallpox and monkeypox that is based on modified vaccinia Ankara has been given the green light for use, but there is only a limited supply of it. In addition, it is important to wash your hands often and stay away from ill people and animals. During an epidemic, antiviral medications like as cidofovir and tecovirimat, as well as vaccinia immune globulin and the smallpox vaccination, may be administered.





Figure 2: Monkeypox

The majority of people who are infected will recover within a few weeks even if they don't get treatment since the sickness is often minor. Estimates of the risk of mortality range from 1% to 10%, however very few fatalities have been documented as a result of monkeypox since 2017. It is hypothesized that a number of different mammalian species serve as natural reservoirs for the virus.[37-39] Although it was originally considered to be rare in humans, the number of outbreaks as well as their intensity has considerably risen since the 1980s. [40] It is possible that this is due to diminishing immunity as a consequence of the cessation of regular smallpox immunization. In 1970, the Democratic Republic of the Congo was the location where researchers discovered the first instances of the disease in people (DRC). There have been isolated incidents of this disease throughout Central and West Africa, but it is prevalent in the Democratic Republic of the Congo. [41] The outbreak of monkeypox in 2022 is the first time that widespread community transmission has occurred outside of Africa. It was first discovered in the United Kingdom in May of that year, and subsequent cases have been confirmed in at least 74 countries across all continents with the exception of Antarctica. The World Health Organization (WHO) declared the outbreak a Public Health Emergency of International Concern (PHEIC) on July 23, 2022. At the time of the declaration, more than 53,000 cases had been reported in 75 countries and territories. [42]

## 2.2 Signs and symptoms

Despite its terrible potential, monkeypox is often a brief, self-limiting viral illness that causes a rash. Most patients get well within a couple of weeks without medical help. It is possible for individuals to get critically ill and even die under certain situations. Symptoms of monkeypox often appear between 5 and 21 days after infection. There may be a progression of symptoms over the course of 2 weeks to 4 weeks. Painful rashes may appear anywhere on the body, including:

- mouth

- genitals
- perianal
- face
- the body's limbs, feet

The rash goes through many phases during the course of its typical 14–28-day duration. At last, scabs develop and eventually fall off. Accompanying the rash may be universal signs such as:

- fever
- chills
- enlarged lymph glands
- headache
- Tense muscles
- aching joints
- hurting back
- exhaustion

From the time the initial symptoms appear until the scabs come off on their own and the skin heals, you will be infectious. [43-44]

### **2.3 Causes**

The monkeypox virus is a member of the Poxviridae family and the genus Orthopoxvirus. It has two strands of DNA and is a double-stranded virus. It has the potential to infect both humans and animals. This virus, which was detected for the first time in monkeys that were held in zoos, is most often found in the tropical rainforests of Central and West Africa. There are two different viral subtypes, and they are clade I and clade II (formerly Congo Basin and West African clades, matching the geographical areas). Dormice (*Graphiurus* spa), African squirrels, and Gambian pouched rats (*Cricetomysgambianus*) have all tested positive for the virus thus far in addition to monkeys (*Heliosciurus*, and *Funisciurus*). Consumption of diseased animals raises significant worries about the possibility of infection in humans. [45]

## 2.4 Diagnosis

- It is important to rule out other rash-causing diseases when making a clinical diagnosis, such as chickenpox, measles, bacterial skin infections, scabies, syphilis, and medication-related allergies. Monkeypox may be distinguished from chickenpox and smallpox by the presence of lymphadenopathy during the prodromal stage of disease. It is possible to confirm a diagnosis by doing a test for the virus.
- It is recommended that samples taken from skin lesions be analyzed by polymerase chain reaction (PCR) testing in the lab. Due to the little period the virus spends in the blood, PCR blood tests are sometimes inconclusive. Date of fever beginning, date of rash commencement, date of specimen collection, stage of rash at time of collection, and patient age are all necessary for interpreting test findings. [46]




Figure 3: PCR Test

## **2.5 Risk Factors**

It's possible that some groups of individuals have a higher chance of getting monkeypox than others. Those who are more likely to develop a severe case of monkeypox include:

**International travelers:** Anyone who goes to an endemic country (areas where the virus has continued circulation) or places with outbreaks is at a higher risk for monkeypox. This includes both domestic and international travelers. [47] If you engage in activities that put you in touch with infected people or animals, the likelihood of contracting the disease increases significantly.

**People who participate in anonymous sexual activity:** Although monkeypox is not considered a sexually transmitted infection (STI) since it may be spread in other ways, it is nevertheless contagious and can be passed on by bodily fluids, close touch, and skin-to-skin contact. The worldwide epidemic that occurred in 2022 was mostly transmitted from person to person via sexual contact.

**People who have contact with animals with the virus:** When a person comes into touch with an infected animal (such as a monkey, rat, or squirrel), there is a risk that they may get monkeypox from that animal and pass it on to themselves. This may happen if you are bitten or scratched by an animal infected with monkeypox. It is also possible to get monkeypox from coming into contact with the lesions or saliva of an infected animal. [48]

**Healthcare workers:** After providing medical attention to a patient who is afflicted with monkeypox, you run the risk of catching the illness yourself. In a medical facility, the virus may be spread by direct contact with a patient's body fluids, lesions, or respiratory droplets. Another mode of transmission is through the spread of respiratory droplets. It is also possible to get it by coming into touch with the clothes or bedding that a person infected with the virus wore. [49]

## **2.6 Prevention**

Because smallpox and monkeypox are closely related viruses, and the vaccine protects animals against experimental deadly monkeypox challenges, it is a commonly held belief that vaccination against smallpox also protects against infection with monkeypox in humans. This is due to the fact that the vaccine protects animals against experimental deadly monkeypox challenges. [50] This has not been demonstrated to be the case in humans since extensive vaccination against smallpox was discontinued when it was reported that the illness had been eliminated. People in Africa who have had the smallpox immunization may have a lower risk of contracting monkeypox compared to those who have not received the vaccination. One explanation for the widespread occurrence of monkeypox is that populations are gradually losing their resistance to poxviruses as a result of

recurrent exposure to these viruses. Cross-protective immunity among people who were inoculated before to 1980. persons is being blamed for this. The Centers for Disease Control and Prevention (CDC) strongly recommends that anybody who will be doing research on monkeypox outbreaks or giving medical treatment to humans or animals who have been infected with monkeypox be vaccinated against smallpox. Anyone who has had direct or intimate contact with a monkeypox carrier, whether the carrier is a human or an animal, should be vaccinated against the disease. Unless they are going to be doing field investigations, the Centers for Disease Control and Prevention (CDC) does not recommend vaccination before to exposure for unknown veterinarians, veterinary personnel, or animal control authorities who may come into contact with the disease. As of the time this article was written, neither the immunization for smallpox nor the vaccination for monkeypox is considered to be safe for use during pregnancy. [51] Before treating an infected patient, medical personnel should dress in full personal protective equipment (PPE), as directed by the Centers for Disease Control and Prevention (CDC). It includes a gown, a mask, goggles, and a respirator that has a filter that can be thrown away after each use (such as an N95).



Figure 4: Respirator

In a perfect world, a person who is infected would be isolated in a chamber with negative air pressure; nevertheless, a private examination room might do in a pinch. [52] Vaccination alone is not sufficient to prevent monkeypox; other measures are necessary. The availability of treatment, the dependability of information, and the quality of health care are all becoming more pressing concerns. Effective communication is perhaps the aspect of public health that presents the biggest challenge. Due to the inherent complex interconnection of the illness as well as the negotiated social meanings, accurate

communication about public health has to be a collaborative effort between medical professionals and people. This is the reason why, as Salving argues in the BMJ, we need a "new ethic of shared responsibility" to warn the public of possible hazards and equip disadvantaged populations with the tools they lack to make informed choices. [53]

## 2.7 Treatment

In both the European Union and the United States, studies have demonstrated that the antiviral medication tecovirimat is effective against a variety of poxviruses, including monkeypox. [54] In addition to supportive care, the antiviral medicine tecovirimat or brincidofovir, which is used to treat smallpox, is recommended as a first-line alternative by BMJ Best Practice in the event that antiviral therapy is required (including antipyretic, fluid balance and oxygenation). An empirical therapy with antibiotics or acyclovir may be offered if it is thought that the patient may develop a future infection with bacteria or varicella zoster. [55]



Figure 5: Tecovirimat

## 2.8 Monkeypox virus

The monkeypox virus is a DNA virus that has the potential to infect people as well as other animals. It is also known as the monkeypox X virus and the human monkeypox X virus. Approximately 190 kilobytes make up the whole of the genome. [56] The monkeypox virus is a member of the family

Orthopoxviridae, which also contains the variola (VARV), cowpox (CPX), and vaccinia (VACV) viruses. These are all viruses that are only remotely related to the monkeypox virus. This virus does not derive directly from the variola virus that causes smallpox, nor does it have a common ancestor with the virus that causes smallpox (variola virus). Although clinically similar to smallpox, monkeypox is characterized by a milder form of the disease's hallmark rash and has a reduced risk of death. [57-59] It is not necessary for an animal and a person to come into touch with one another for the virus to be transmitted from animal to human. [60] Even though monkeys were the first animals to be infected with the virus that would later be recognized as monkeypox, rodents are currently considered to be the most frequent reservoir hosts. It has been shown that the virus exhibits some degree of virulence variation, as it has been found that isolates from Central Africa have a greater virulence than isolates from Western Africa. The virus has now divided into two clades, one of which is unique to each location. These clades were once known as the clade that originated in the Congo Basin (Central Africa) and the clade that originated in West Africa, respectively. [61]




Figure 6: Monkeypox virus

## 2.9 Virology

### Classification

The World Health Organization (WHO) has placed MPV on its list of illnesses that have the potential to become epidemic or pandemic. MPV is classified as a member of the genus Orthopoxvirus, which is part of the Poxviridae family. [62]




Figure 7: Orthopoxvirus

The monkeypox virus, like other poxviruses, has an oval shape and an exterior membrane that is composed of a lipoprotein. Enzymes, DNA, and transcription factors of the virus are shielded from the outside environment by the virus's outer membrane. [63] The genome of the monkeypox virus is around 200 kilobytes in size and encodes for about 200 different proteins. It possesses double-stranded DNA that is presented in the form of a linear structure with covalently closed hairpin ends; the 3' and 5' ends are not free. [64] The irons of monkey pox have huge oval-shaped envelopes, much like the irons of other poxviruses. The 3' and 5' ends are not free. A core can be found inside of every virion, and this core contains the genome in addition to the enzymes that aid in the process of replicating and removing the protein coat. [65]






Figure 8: Poxviruses

### Replication and life cycle

Gene expression begins when MPV releases viral proteins and enzymatic factors that disable the cell. Protein synthesis allows for the ER membrane of the factory to disassemble. As an orthopoxvirus, MPV replication takes place entirely in the cell cytoplasm within 'factories' created from the host rough endoplasmic reticulum (ER), where viral mRNA transcription and translation also take place. [66]

# **Chapter Three**

## Purpose of the study

### **3.1 Purpose of the study**

Purpose of the study is,

1. to view the percentage of deaths from monkey pox worldwide.
2. to calculate the prevalence of monkeypox.
3. to overview about managing and treating monkeypox.
4. to open a new area of higher studies
5. to gain a thorough understanding of the disease, including its cause, signs and symptoms, consequences and medical and treatment choices.
6. the purpose of this research was to understand more about monkeypox.

# **Chapter Four**

## **Methodology**

#### **4.1 Introduction:**

A literature review leads the examination. Around 105 papers are reviewed for this study.

#### **4.2 Research Design:**

This exploration was planned through google scholar and many other websites to find literature.

#### **4.3 Method of Data Analysis:**

After compiling a large amount of information, it was examined for accuracy and coherence within itself to rule out the possibility of missing or conflicting data, both of which were afterward thrown out. The Microsoft Dominant Refreshed Version was used in the information inquiry that was carried out. All of the information gathered is from 1990 all the way until 2022.

#### **4.4 Ethical Considerations:**

Before beginning the process of information collection, informed verbal consent was obtained from those participating in the inquiry. A veil of secrecy was maintained over the identities of those who participated in the research, and participants in the studies were informed that they were free to withdraw from the program at any point throughout the process of data collection. The inquiry garnered the backing of the Department of Pharmacy.

# **Chapter Five**

## **Result and Discussion**

## 5.1 Deaths caused by monkey pox globally

Country Name	Number of Cases	Number of deaths
Argentina	1112	2
Belgium	793	2
Bolivia	265	2
Brazil	10878	15

Table 1: Deaths caused by monkey pox globally

In 2022, monkey pox spread widely, with most victims residing in Africa, claims a review article. Bolivia has 265 cases and two fatalities confirmed, Argentina has 1112 cases and two fatalities confirmed, Belgium has 793 cases and two fatalities confirmed, and Brazil has 10878 cases and fifteen fatalities confirmed. [82].

## 5.2. Clinical Characteristics of Smallpox, Monkeypox, and Varicella

Characteristic	Smallpox	Monkeypox	Varicella
Incubation period	7–17 d	7–17 d	10–21 d
Rash period (from the appearance of lesions to desquamation)	14–28 d	14–28 d	10–21 d
Prodromal fever	Yes	Yes	Uncommon, mild fever if present
Fever	Yes, often >40°C	Yes, often between 38.5°C and 40.5°C	Yes, up to 38.8°C

Table 2: Clinical Characteristics of Smallpox, Monkeypox, and Varicella

The incubation times for smallpox, monkeypox, and varicella are 7–17 days, 10–21 days, and 10–21 days, respectively. Smallpox, monkeypox, and varicella all cause rashes that last 14–28 days, 10–21 days, and 10–21 days, respectively. Smallpox and monkeypox prodromal fevers reach fever levels of over 40°C, whereas varicella prodromal fever is mild. Moreover, the varicella virus increases body temperatures to a maximum of 38.8°C, which are often between 38.5°C and 40.5°C. [83]

### 5.3 Summary of therapies for the management of monkeypox

Treatments	Route	Dosing
Tecovirimat	PO, IV (approved in May 2022)	Adults: 600 mg twice daily for 14 days; pediatrics (13 kg or more), if 13 kg to less than 25 kg: 200 mg BID for 14 days, if 25 kg to less than 40 kg: 400 mg twice daily for 14 days, if 40 kg or more: 600 mg twice daily for 14 days
Brincidofovir	PO (tablets, oral suspension)	Adults weighing $\geq 48$ kg: 200 mg once weekly for two doses; adults and pediatric patients weighing $\geq 10$ kg to less than 48 kg: 4 mg/kg of the oral suspension once weekly for two doses; pediatrics weighing less than 10 kg, the dose is 6 mg/kg of the oral suspension once weekly for 2 doses
Cidofovir	IV	5 mg/kg once weekly for 2 weeks, followed by 5 mg/kg IV once every other week
Vaccinia immune globulin	IV	6000 U/kg as soon as symptoms appears; may repeated based on severity of symptoms and response to treatment; 9000 U/kg may be considered if patient does not respond to initial dose

Table 3: Summary of therapies for the management of monkeypox

According to a review study, the first antiviral authorized for the treatment of smallpox in adults and pediatric patients weighing at least 3 kg is Tecovirimat (also known as TPOXX or ST-246),



which is regarded as the preferred treatment. The oral equivalent of the intravenous medicine cidofovir, brincidofovir, has been approved for the treatment of smallpox in the US. Brincidofovir may have a better safety profile than cidofovir, including less kidney damage [85].

#### 5.4 Monkeypox Patients with Seminal Fluid Viral DNA

Sexual Orientation	Concomitant STI (Site)	HIV Status
Homosexual	None	Positive
Bisexual	None	Negative
Homosexual	None	Positive
Homosexual	Gonorrhea (penis)	Negative

Table 4: Monkeypox Patients with Seminal Fluid Viral DNA

According to review an article, Monkeypox Patients with Seminal Fluid Viral DNA had HIV positive or other sexual transmission infection (STI), The all most all patients are homosexual or bisexual [86].

# **Chapter 6**

# **Conclusion**

## **6.1 Conclusion**

Monkeypox is a rare viral disease that mostly affects remote areas of Central and West Africa. The smallpox-related monkeypox virus, which causes it, is the cause. The condition, which causes a rash, fever, headache, and muscular pains, has no recognized cure. One technique of protection is avoiding contact with animals that might be infected with the virus. Another is exercising additional caution when handling animals or animal products by using gloves and safety equipment. There is a monkeypox vaccine, however it is mostly used in clinical and laboratory settings and is not often available to the general public.

# **Chapter seven**

## Reference

## 7.1 Reference

1. Wu KJ (15 April 2020). "There are more viruses than stars in the universe. Why do only some infect us? – More than a quadrillion quadrillion individual viruses exist on Earth, but most are not poised to hop into humans. Can we find the ones that are?". National Geographic Society. Retrieved 18 May 2020.
2. Koonin EV, Senkevich TG, Dolja VV (September 2006). "The ancient Virus World and evolution of cells". *Biology Direct*. 1 (1): 29. doi:10.1186/1745-6150-1-29. PMC 1594570. PMID 16984643.
3. Zimmer C (26 February 2021). "The Secret Life of a Coronavirus - An oily, 100-nanometer-wide bubble of genes has killed more than two million people and reshaped the world. Scientists don't quite know what to make of it". *The New York Times*. Archived from the original on 28 December 2021. Retrieved 28 February 2021. "Virus Taxonomy: 2021 Release". [talk.ictvonline.org](http://talk.ictvonline.org). International Committee on Taxonomy of Viruses. Retrieved 4 April 2022.
4. Breitbart M, Rohwer F (June 2005). "Here a virus, there a virus, everywhere the same virus?". *Trends in Microbiology*. 13 (6): 278–84. doi:10.1016/j.tim.2005.04.003. PMID 15936660.
5. Lawrence CM, Menon S, Eilers BJ, Bothner B, Khayat R, Douglas T, Young MJ (May 2009). "Structural and functional studies of archaeal viruses". *The Journal of Biological Chemistry*. 284 (19): 12599–603. doi:10.1074/jbc.R800078200. PMC 2675988. PMID 19158076.
6. Edwards RA, Rohwer F (June 2005). "Viral metagenomics". *Nature Reviews Microbiology*. 3 (6): 504–10. doi:10.1038/nrmicro1163. PMID 15886693. S2CID 8059643.
7. Canchaya C, Fournous G, Chibani-Chennoufi S, Dillmann ML, Brüssow H (August 2003). "Phage as agents of lateral gene transfer". *Current Opinion in Microbiology*. 6 (4): 417–24. doi:10.1016/S1369-5274(03)00086-9. PMID 12941415.
8. Rybicki EP (1990). "The classification of organisms at the edge of life, or problems with virus systematics". *South African Journal of Science*. 86: 182–86.
9. Koonin EV, Starokadomskyy P (October 2016). "Are viruses alive? The replicator paradigm sheds decisive light on an old but misguided question". *Studies in History*

- and *Philosophy of Biological and Biomedical Sciences*. 59: 125–34. doi:10.1016/j.shpsc.2016.02.016. PMC 5406846. PMID 26965225.
10. Robilotti E, Deresinski S, Pinsky BA (January 2015). "Norovirus". *Clinical Microbiology Reviews*. 28 (1): 134–64. doi:10.1128/CMR.00075-14. PMC 4284304. PMID 25567225.
  11. Mahy WJ, Regenmortel MH, eds. (2009). *Desk Encyclopedia of General Virology*. Oxford: Academic Press. p. 24. ISBN 978-0-12-375146-1.
  12. Shors p. 810
  13. McClintock B (June 1950). "The origin and behavior of mutable loci in maize". *Proceedings of the National Academy of Sciences of the United States of America*. 36 (6): 344–55. Bibcode:1950PNAS...36..344M. doi:10.1073/pnas.36.6.344. PMC 1063197. PMID 15430309.
  14. Tsagris EM, Martínez de Alba AE, Gozmanova M, Kalantidis K (November 2008). "Viroids". *Cellular Microbiology*. 10 (11): 2168–79. doi:10.1111/j.1462-5822.2008.01231.x. PMID 18764915. S2CID 221581424.
  15. La Scola B, Desnues C, Pagnier I, Robert C, Barrassi L, Fournous G, et al. (September 2008). "The virophage as a unique parasite of the giant mimivirus". *Nature*. 455 (7209): 100–04. Bibcode:2008Natur.455..100L. doi:10.1038/nature07218. PMID 18690211. S2CID 4422249.
  16. Mahy WJ, Van Regenmortel MH, eds. (2009). *Desk Encyclopedia of General Virology*. Oxford: Academic Press. p. 28. ISBN 978-0-12-375146-1.
  17. Mahy WJ, Regenmortel MH, eds. (2009). *Desk Encyclopedia of General Virology*. Oxford: Academic Press. p. 26. ISBN 978-0-12-375146-1.
  18. "Transmission Monkeypox". CDC. 11 May 2015. Archived from the original on 15 October 2017. Retrieved 15 October 2017.
  19. "Treatment Monkeypox Poxvirus CDC". www.cdc.gov. 28 December 2018. Archived from the original on 15 June 2019. Retrieved 11 October 2019.
  20. James, William D.; Elston, Dirk; Treat, James R.; Rosenbach, Misha A.; Neuhaus, Isaac (2020). "19. Viral diseases". *Andrews' Diseases of the Skin: Clinical Dermatology* (13th ed.). Edinburgh: Elsevier. p. 389. ISBN 978-0-323-54753-6.

21. Bunge, Eveline M.; Hoet, Bernard; Chen, Liddy; Lienert, Florian; Weidenthaler, Heinz; Baer, Lorraine R.; Steffen, Robert (11 February 2022). "The changing epidemiology of human monkeypox – A potential threat? A systematic review". *PLOS Neglected Tropical Diseases*. 16 (2): e0010141. doi:10.1371/journal.pntd.0010141. PMC 8870502. PMID 35148313.
22. "Monkeypox". CDC. 11 May 2015. Archived from the original on 15 October 2017. Retrieved 15 October 2017.
23. "Monkeypox outbreak: List of countries with reported cases". Gulf News. Retrieved 24 May 2022.
24. "Viruela del mono: confirmaron el primer caso del virus en el país" (in Spanish). 26 May 2022. Retrieved 26 May 2022.
25. Efrati, Ido. "Israel Confirms First Case of Monkeypox Virus". Haaretz. Retrieved 21 May 2022.
26. "Morocco Reports First Monkeypox Case". Morocco World News. Retrieved 2 June 2022.
27. Grover, Natalie; Revill, John; Rigby, Jennifer (23 July 2022). "Monkeypox outbreak constitutes global health emergency – WHO". Reuters. Retrieved 23 July 2022.
28. Kantele A, Chickering K, Vapalahti O, Rimoin AW (August 2016). "Emerging diseases-the monkeypox epidemic in the Democratic Republic of the Congo". *Clinical Microbiology and Infection*. 22 (8): 658–659. doi:10.1016/j.cmi.2016.07.004. PMC 9533887. PMID 27404372.
29. "New Monkeypox Symptoms Are Making Cases Harder to Recognize". Bloomberg.com. 2022-07-21. Retrieved 2022-07-21.
30. Falendysz, Elizabeth A.; Lopera, Juan G.; Lorenzsonn, Faye; Salzer, Johanna S.; Hutson, Christina L.; Doty, Jeffrey; Gallardo-Romero, Nadia; Carroll, Darin S.; Osorio, Jorge E.; Roche, Tonie E. (30 October 2015). "Further Assessment of Monkeypox Virus Infection in Gambian Pouched Rats (*Cricetomys gambianus*) Using In Vivo Bioluminescent Imaging". *PLOS Neglected Tropical Diseases*. 9 (10): e0004130. doi:10.1371/journal.pntd.0004130. PMC 4627722. PMID 26517839.

31. "WHO Factsheet – Monkeypox". World Health Organization. 19 May 2022. Retrieved 28 May 2022.
32. Angelo KM, Petersen BW, Hamer DH, Schwartz E, Brunette G. Monkeypox transmission among international travellers-serious monkey business? *J Travel Med.* 2019;26(5):taz002. doi:10.1093/jtm/taz002
33. Centers for Disease Control and Prevention. Safer sex, social gatherings, and monkeypox.
34. World Health Organization. Multi-country monkeypox outbreak: situation update.
35. Marriott, Kathleen A.; Parkinson, Christopher V.; Morefield, Samantha I.; Davenport, Robert; Nichols, Richard; Monath, Thomas P. (January 2008). "Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge". *Vaccine.* 26 (4): 581–588. doi:10.1016/j.vaccine.2007.10.063. PMC 9533847. PMID 18077063.
36. Khalil A, Samara A, O'Brien P, Morris E, Draycott T, Lees C, Ladhani S (June 2022). "Monkeypox vaccines in pregnancy: lessons must be learned from COVID-19". *The Lancet. Global Health.* 10 (9): e1230–e1231. doi:10.1016/S2214-109X(22)00284-4. PMC 9236565. PMID 35772413.
37. "Infection Control: Hospital | Monkeypox | Poxvirus | CDC". 2019-01-03. Retrieved 2022-05-21.
38. Scalvini, Marco (2022-09-14). "Monkeypox: patients, clinicians, and the need for shared responsibility". *BMJ.* 378: o2221. doi:10.1136/bmj.o2221. ISSN 1756-1833. PMID 36104032. S2CID 252216252.
39. "Tecovirimat SIGA". European Medicines Agency. 28 January 2022. Archived from the original on 16 May 2022. Retrieved 19 May 2022.
40. ^ "Poxvirus infection (monkeypox and smallpox) - Treatment algorithm | BMJ Best Practice". *bestpractice.bmj.com.* Retrieved 2022-05-20.
41. "Factsheet for health professionals on monkeypox". European Centre for Disease Prevention and Control. Retrieved 2022-10-09.
42. Breman JG, Steniowski MV, Zanotto E, Gromyko AI, Arita I (1980). "Human monkeypox, 1970-79". *Bulletin of the World Health Organization.* 58 (2): 165–182. PMC 2395797. PMID 6249508.



43. Alkhalil A, Hammamieh R, Hardick J, Ichou MA, Jett M, Ibrahim S (July 2010). "Gene expression profiling of monkeypox virus-infected cells reveals novel interfaces for host-virus interactions". *Virology Journal*. 7: 173. doi:10.1186/1743-422X-7-173. PMC 2920256. PMID 20667104.
44. Shchelkunov SN, Totmenin AV, Safronov PF, Mikheev MV, Gutorov VV, Ryazankina OI, et al. (June 2002). "Analysis of the monkeypox virus genome". *Virology*. 297 (2): 172–194. doi:10.1006/viro.2002.1446. PMC 9534300. PMID 12083817.
45. CDC (2022-10-18). "Monkeypox in the U.S." Centers for Disease Control and Prevention. Retrieved 2022-10-26.
46. "Monkeypox: experts give virus variants new names". [www.who.int](http://www.who.int). Retrieved 2022-08-19.
47. Lansiaux, Edouard; Jain, Nityanand; Laivacuma, Sniedze; Reinis, Aigars (2022-12-01). "The virology of human monkeypox virus (hMPXV): A brief overview". *Virus Research*. 322: 198932. doi:10.1016/j.virusres.2022.198932. ISSN 0168-1702. PMC 9534104. PMID 36165924.
48. ^ Alakunle E, Moens U, Nchinda G, Okeke MI (November 2020). "Monkeypox Virus in Nigeria: Infection Biology, Epidemiology, and Evolution". *Viruses*. 12 (11): 1257. doi:10.3390/v12111257. PMC 7694534. PMID 33167496.
49. ^ Kugelman JR, Johnston SC, Mulembakani PM, Kisalu N, Lee MS, Koroleva G, et al. (February 2014). "Genomic variability of monkeypox virus among humans, Democratic Republic of the Congo". *Emerging Infectious Diseases*. 20 (2): 232–239. doi:10.3201/eid2002.130118. PMC 3901482. PMID 24457084.
50. ^ "Monkeypox: What We Do and Don't Know About Recent Outbreaks". [ASM.org](http://ASM.org). Retrieved 2022-10-21.
51. ^ Jump up to:a b c "Monkeypox: What We Do and Don't Know About Recent Outbreaks". [ASM.org](http://ASM.org). Retrieved 2022-10-26.
52. Parker S, Buller RM (February 2013). "A review of experimental and natural infections of animals with monkeypox virus between 1958 and 2012". *Future Virology*. 8 (2): 129–157. doi:10.2217/fvl.12.130. PMC 3635111. PMID 23626656.

53. "Monkeypox". *New Scientist*. Reed Business Information. 80: 682–. 30 November 1978. ISSN 0262-4079.
54. "2003 U.S. Outbreak Monkeypox". CDC. 11 May 2015. Archived from the original on 15 October 2017. Retrieved 15 October 2017.
55. Igiebor FA, Agbontaen OJ, Egharevba PA, Amengialue OO, Ehiaghe JI, Ovwero E, Ehiaghe FA (May 2022). "Monkeypox: Emerging and Re-Emerging Threats in Nigeria". *Journal of Basic and Applied Sciences*. Benin City, Nigeria: Faculty of Science, Benson Idahosa University. 7 (1): 119–132.
56. Meyer H, Perrichot M, Stemmler M, Emmerich P, Schmitz H, Varaine F, et al. (August 2002). "Outbreaks of disease suspected of being due to human monkeypox virus infection in the Democratic Republic of Congo in 2001". *Journal of Clinical Microbiology*. 40 (8): 2919–2921. doi:10.1128/JCM.40.8.2919-2921.2002. PMC 120683. PMID 12149352.
57. Ogoina D, Izibewule JH, Ogunleye A, Ederiane E, Anebonam U, Neni A, Oyeyemi A, Etebu EN, Ihekweazu C (2019). "The 2017 human monkeypox outbreak in Nigeria-Report of outbreak experience and response in the Niger Delta University Teaching Hospital, Bayelsa State, Nigeria". *PLOS ONE*. 14 (4): e0214229
58. Bibcode:2019PLoSO..1414229O. doi:10.1371/journal.pone.0214229. PMC 6469755. PMID 30995249.
59. Scribner, Herb (20 May 2022). "HHS says recent U.S. smallpox vaccine order not related to monkeypox outbreak". *Axios*. Archived from the original on 20 May 2022. Retrieved 22 May 2022.
60. Güell, Oriol (19 May 2022). "España prepara la compra de miles de vacunas contra la viruela tradicional para hacer frente al brote del virus del mono". *El País* (in Spanish). Archived from the original on 26 May 2022. Retrieved 26 May 2022.
61. "Germany orders 40,000 vaccine doses as precaution against monkeypox spread". *Reuters*. 24 May 2022. Archived from the original on 24 May 2022. Retrieved 26 May 2022.
62. "Britain's UKHSA says it has procured 20,000 doses of vaccine against monkeypox". *Reuters*. 26 May 2022. Archived from the original on 26 May 2022. Retrieved 26 May 2022.

63. Rao, Agam K. (2022). "Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022". *MMWR. Morbidity and Mortality Weekly Report*. 71 (22): 734–742. doi:10.15585/mmwr.mm7122e1. ISSN 0149-2195. PMC 9169520. PMID 35653347. S2CID 249142212. Archived from the original on 31 May 2022. Retrieved 28 May 2022
64. "Monkeypox Vaccine Clinic for People Who May Have Been Exposed to Monkeypox – NYC Health". [www1.nyc.gov](http://www1.nyc.gov). Archived from the original on 27 June 2022. Retrieved 23 June 2022.
65. U.S. to release 786,000 additional monkeypox vaccine doses as outbreak spreads
66. Exclusive: Closure of World's Only Manufacturing Plant for Monkeypox Vaccine Raises Questions About World's Ability to Meet Rising Demand